BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
02 janv. 2024 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
11 déc. 2023 08h00 HE
|
AiViva Biopharma
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced...
BetterLife Announces Extension of Warrants
30 nov. 2023 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech mun birta uppgjör fyrstu níu mánaða 2023 þann 28. nóvember og streyma uppgjörsfundi 29. nóvember kl. 13:00 að íslenskum tíma
21 nov. 2023 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) mun birta uppgjör fyrir fyrstu níu mánuði ársins 2023 eftir lokun markaða í Bandaríkjunum, þriðjudaginn 28. nóvember 2023. Þá mun Alvotech halda kynningarfund fyrir fjárfesta...
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
21 nov. 2023 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
15 nov. 2023 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
03 oct. 2023 05h00 HE
|
Alvotech
REYKJAVIK, Iceland and PISCATAWAY, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
02 oct. 2023 07h30 HE
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
Senti Bio to Participate in Upcoming Conferences
26 sept. 2023 16h05 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
25 sept. 2023 04h00 HE
|
Alvotech
REYKJAVIK, Iceland, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...